What is the recommended norepinephrine infusion dosage and titration protocol for an adult with hypotension (e.g., septic shock)?

Norepinephrine Dosing in Septic Shock

Start norepinephrine at 8-12 mcg/min (0.05-0.1 mcg/kg/min), titrate to achieve MAP ≥65 mmHg, with typical maintenance doses of 2-4 mcg/min (0.03-0.05 mcg/kg/min), though doses can safely escalate to >1 mcg/kg/min in refractory shock. 1, 2

Initial Dosing Protocol

The FDA-approved dosing regimen provides clear guidance 1:

• Preparation: Dilute 4 mg norepinephrine in 1000 mL of 5% dextrose solution (yielding 4 mcg/mL concentration)
• Starting dose: 8-12 mcg/min (2-3 mL/min of diluted solution)
• Maintenance range: 2-4 mcg/min (0.5-1 mL/min)
• Administration: Via central venous catheter into a large vein with continuous infusion pump

Target Blood Pressure

Target MAP of 65 mmHg initially 2. However, individualize based on:

• Chronic hypertension: Aim for no more than 40 mmHg below baseline systolic pressure 1
• Higher targets may be needed: In patients with history of hypertension, consider MAP 70-80 mmHg 3, 4

The Surviving Sepsis Campaign guidelines provide strong recommendation (Grade 1C) for the 65 mmHg MAP target 2.

Titration Strategy

Titrate every 2-5 minutes based on hemodynamic response 1:

• Monitor MAP continuously via arterial line (strongly recommended when vasopressors are used) 2
• Assess urine output (target ≥0.5 mL/kg/h)
• Follow lactate trends (aim for ≥10% decrease from baseline) 5
• Adjust dose to maintain adequate organ perfusion, not just arbitrary pressure targets

Timing Considerations

Start norepinephrine early—within 1 hour of shock recognition—rather than waiting for complete fluid resuscitation 5, 6. The CENSER trial demonstrated that early norepinephrine (median 93 minutes from ED arrival) achieved:

• 76% shock control by 6 hours vs 48% with delayed initiation (p<0.001)
• Lower incidence of pulmonary edema (14% vs 28%)
• Reduced new-onset arrhythmias (11% vs 20%) 5

Recent meta-analysis confirms early initiation reduces mortality (OR 0.49), particularly when lactate ≤3 mmol/L and administered within 1 hour 6.

High-Dose Management

Do not hesitate to escalate doses in refractory shock 2, 3:

• Doses up to 1-2 mcg/kg/min are commonly needed
• Doses as high as 68 mg/day (approximately 0.5-1 mcg/kg/min continuously) have been used safely 1, 7
• Before escalating beyond 0.25-0.5 mcg/kg/min, add vasopressin 0.03 units/min 2, 8

The guidelines suggest adding vasopressin or epinephrine when norepinephrine requirements increase, rather than continuing to escalate norepinephrine alone (weak recommendation, moderate quality evidence) 2.

Critical Pitfalls to Avoid

Volume status assessment is paramount: Always suspect occult hypovolemia in patients requiring escalating doses 1. Central venous pressure monitoring helps detect this 1.

Dilution matters:

• Use 5% dextrose or dextrose-saline solutions only (protects against oxidation) 1
• Never use saline alone 1
• Adjust concentration based on fluid tolerance (more concentrated if fluid-restricted, more dilute if large volumes needed)

Avoid abrupt discontinuation: Taper gradually to prevent rebound hypotension 1. When weaning dual vasopressors, either norepinephrine or vasopressin can be discontinued first without significant difference in 6-hour hypotension rates 9.

Renal protection: Norepinephrine actually improves renal function in septic shock—creatinine clearance increased from 75 to 102 mL/min in one study 10. Do not withhold due to renal concerns.

Hemodynamic Effects

Norepinephrine increases 10:

• Mean arterial pressure and systemic vascular resistance (primary effect)
• Stroke volume (after 8 hours of therapy)
• Glomerular filtration rate

It does NOT significantly impair:

• Cardiac output (remains stable or improves)
• Oxygen delivery or consumption
• Tissue perfusion when MAP is restored

When Norepinephrine Fails

If MAP target not achieved despite norepinephrine 0.25-0.5 mcg/kg/min 2, 8:

1. Add vasopressin 0.03 units/min (weak recommendation, moderate quality evidence)
2. Consider epinephrine as alternative second agent (weak recommendation, low quality evidence)
3. Factors predicting poor AVP response: obesity (BMI), hyperlactatemia, lower pH 8
4. Continue escalating norepinephrine if needed—doses >1 mcg/kg/min are safe 3, 7